Aspirin Use Tied to Lower Risks of Several GI Cancers- A sys
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
An updated comprehensive systematic review and meta-analysis of observational studies published in Annals of Oncology found that regular use of aspirin was associated with a reduced risk of several GI cancers, with a dose effect seen with CRC.

Based on pooled data from 113 studies, Cristina Bosetti, MD, Milan, Italy, and colleagues found that taking one or two aspirin per week was associated with the following risk reductions:

-- 22% reduction in the risk of pancreatic cancer
-- 27% reduction in the risk of CRC
-- 33% reduction in the risk of squamous-cell esophageal cancer
-- 36% reduction in the risk of stomach cancer
-- 38% reduction in the risk of hepatobiliary tract cancer
-- 39% reduction in the risk of adenocarcinoma of the esophagus and gastric cardia

The number of eligible studies ranged from five on hepatobiliary cancer to 45 on colorectal cancer. Risk estimates were consistent across sex, geographical areas, and other covariates. The association between head and neck cancer and aspirin use was also studied, but no risk reduction was observed.

Taking aspirin for the prevention of bowel cancer, or any other cancers, should only be done in consultation with a doctor, who can take account of the person's individual risk. This includes factors such as sex, age, a family history of a first-degree relative with the disease, and other risk factors. People who are at high risk of the disease are most likely to gain the greatest benefits from aspirin.

Source: https://www.annalsofoncology.org/article/S0923-7534(20)36073-7/fulltext
Dr. A●●●●●l s●●●●a and 1 others like this3 shares
Like
Comment
Share